Summary of clinical therapeutic effects and patient feedback of Trelagliptin

Trelagliptin (Trelagliptin) is a long-acting dipeptidyl peptidase-4 (DPP-4) inhibitor, mainly used to treat patients with type 2 diabetes. Its mechanism of action is to inhibit DPP-4enzyme activity, prolong glucagon-like peptide-1 (GLP-1) and The action time of glucose-dependent insulinotropicpolypeptide (GIP) enhances insulin secretion from pancreatic beta cells and inhibits glucagon secretion, thereby improving blood sugar control. The long-acting nature of trotagliptin allows it to be taken only once a day, significantly improving patient compliance.

Clinical trial data show that tretagliptin, when used as a monotherapy or in combination with other oral antidiabetic drugs (such as metformin), can effectively reduce fasting blood glucose and postprandial blood glucose levels, and show stable improvement in HbA1c control. In multiple randomized controlled trials, patients' average HbA1cHbA1c< /span>The decrease range is about 0.7% to 1.0%, and the incidence of hypoglycemia is significantly lower than that of sulfonylurea drugs. It has stable blood sugar control effect and is safe at the same time. It is especially suitable for middle-aged and elderly patients or patients at risk of hypoglycemia.

Feedback from patients shows that the once-daily oral administration of trolagliptin improves the convenience of medication. Patients generally report that after taking the medication, their daily routine has improved, blood sugar fluctuations have decreased, and their daily diet and quality of life have been maintained. In addition, some patients also reported that there was no significant change in weight while taking tretagliptin, and there were few side effects. Common adverse reactions were mainly mild upper respiratory tract infection, headache or digestive discomfort. Most patients could tolerate it and did not need to stop taking the drug.

In summary, trolagliptin has the characteristics of stable blood sugar control, low risk of hypoglycemia, high compliance and good safety in the clinical treatment of type 2 diabetes. Patient feedback has been positive in real-world use, particularly showing significant advantages in maintaining glycemic control as a combination therapy or as a single agent. Its once-daily medication regimen not only facilitates long-term patient compliance, but also helps improve the quality of life. It is one of the commonly used DPP-4 inhibitors in clinical practice.

Reference link:https://www.drugs.com